Dedifferentiation in the metastatic progression of prostate carcinoma

Liang Cheng, Jeff Slezak, Erik J. Bergstralh, John C. Cheville, Susan Sweat, Horst Zincke, David G. Bostwick

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

BACKGROUND. Dedifferentiation is a distinctive feature of cancer progression. Detailed histologic analysis of primary prostate carcinoma and synchronous lymph node metastases may improve our understanding of the complex process of cancer progression and metastasis. METHODS. The authors studied 242 regional lymph node positive prostate carcinoma patients who underwent radical prostatectomy and bilateral lymphadenectomy between 1987 and 1992 at the Mayo Clinic. Patients ranged in age from 47-79 years (median, 66 years). The median follow-up was 6.1 years. Gleason scores of lymph node metastases and primary tumors were compared and correlated with systemic disease progression. Histologic dedifferentiation was defined as a higher Gleason grade in the lymph node metastases than in the primary tumor. Systemic disease progression was defined as the presence of distant metastases documented by biopsies, abdominal computed tomography, plain radiograph, or bone scan. RESULTS. The 5-year systemic progression free survival (PFS) rate was 90%. The Gleason score in the lymph node metastases was higher than in the primary tumor in 45% of patients, lower in 12% of patients, and matched exactly in 43% of patients. The 5-year PFS was significantly different between patients with histologic dedifferentiation (88% ± 3) and those without dedifferentiation (94% ± 2) (P = 0.04). Adjusting for the Gleason grade of the primary tumor and total lymph node tumor volume, the relative risk for disease progression associated with dedifferentiation was 1.8 (95% confidence interval, 0.7-4.7; P = 0.25). CONCLUSIONS. The findings of the current study demonstrate the morphologic heterogeneity of metastases from prostate carcinoma. There is a trend toward histologic dedifferentiation when prostate carcinoma metastasizes to regional lymph nodes. This dedifferentiation, although univariately significant, was not associated with disease progression when adjusted for lymph node tumor volume.

Original languageEnglish
Pages (from-to)657-663
Number of pages7
JournalCancer
Volume86
Issue number4
DOIs
StatePublished - Aug 15 1999

Fingerprint

Prostate
Lymph Nodes
Carcinoma
Neoplasm Metastasis
Disease Progression
Neoplasms
Neoplasm Grading
Tumor Burden
Disease-Free Survival
Prostatectomy
Lymph Node Excision
Survival Rate
Tomography
Confidence Intervals
Biopsy
Bone and Bones

Keywords

  • Dedifferentiation
  • Metastasis
  • Progression
  • Prostate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cheng, L., Slezak, J., Bergstralh, E. J., Cheville, J. C., Sweat, S., Zincke, H., & Bostwick, D. G. (1999). Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer, 86(4), 657-663. https://doi.org/10.1002/(SICI)1097-0142(19990815)86:4<657::AID-CNCR15>3.0.CO;2-9

Dedifferentiation in the metastatic progression of prostate carcinoma. / Cheng, Liang; Slezak, Jeff; Bergstralh, Erik J.; Cheville, John C.; Sweat, Susan; Zincke, Horst; Bostwick, David G.

In: Cancer, Vol. 86, No. 4, 15.08.1999, p. 657-663.

Research output: Contribution to journalArticle

Cheng, L, Slezak, J, Bergstralh, EJ, Cheville, JC, Sweat, S, Zincke, H & Bostwick, DG 1999, 'Dedifferentiation in the metastatic progression of prostate carcinoma', Cancer, vol. 86, no. 4, pp. 657-663. https://doi.org/10.1002/(SICI)1097-0142(19990815)86:4<657::AID-CNCR15>3.0.CO;2-9
Cheng, Liang ; Slezak, Jeff ; Bergstralh, Erik J. ; Cheville, John C. ; Sweat, Susan ; Zincke, Horst ; Bostwick, David G. / Dedifferentiation in the metastatic progression of prostate carcinoma. In: Cancer. 1999 ; Vol. 86, No. 4. pp. 657-663.
@article{51290eca6f3a4233ab851af52edf7bb5,
title = "Dedifferentiation in the metastatic progression of prostate carcinoma",
abstract = "BACKGROUND. Dedifferentiation is a distinctive feature of cancer progression. Detailed histologic analysis of primary prostate carcinoma and synchronous lymph node metastases may improve our understanding of the complex process of cancer progression and metastasis. METHODS. The authors studied 242 regional lymph node positive prostate carcinoma patients who underwent radical prostatectomy and bilateral lymphadenectomy between 1987 and 1992 at the Mayo Clinic. Patients ranged in age from 47-79 years (median, 66 years). The median follow-up was 6.1 years. Gleason scores of lymph node metastases and primary tumors were compared and correlated with systemic disease progression. Histologic dedifferentiation was defined as a higher Gleason grade in the lymph node metastases than in the primary tumor. Systemic disease progression was defined as the presence of distant metastases documented by biopsies, abdominal computed tomography, plain radiograph, or bone scan. RESULTS. The 5-year systemic progression free survival (PFS) rate was 90{\%}. The Gleason score in the lymph node metastases was higher than in the primary tumor in 45{\%} of patients, lower in 12{\%} of patients, and matched exactly in 43{\%} of patients. The 5-year PFS was significantly different between patients with histologic dedifferentiation (88{\%} ± 3) and those without dedifferentiation (94{\%} ± 2) (P = 0.04). Adjusting for the Gleason grade of the primary tumor and total lymph node tumor volume, the relative risk for disease progression associated with dedifferentiation was 1.8 (95{\%} confidence interval, 0.7-4.7; P = 0.25). CONCLUSIONS. The findings of the current study demonstrate the morphologic heterogeneity of metastases from prostate carcinoma. There is a trend toward histologic dedifferentiation when prostate carcinoma metastasizes to regional lymph nodes. This dedifferentiation, although univariately significant, was not associated with disease progression when adjusted for lymph node tumor volume.",
keywords = "Dedifferentiation, Metastasis, Progression, Prostate",
author = "Liang Cheng and Jeff Slezak and Bergstralh, {Erik J.} and Cheville, {John C.} and Susan Sweat and Horst Zincke and Bostwick, {David G.}",
year = "1999",
month = "8",
day = "15",
doi = "10.1002/(SICI)1097-0142(19990815)86:4<657::AID-CNCR15>3.0.CO;2-9",
language = "English",
volume = "86",
pages = "657--663",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Dedifferentiation in the metastatic progression of prostate carcinoma

AU - Cheng, Liang

AU - Slezak, Jeff

AU - Bergstralh, Erik J.

AU - Cheville, John C.

AU - Sweat, Susan

AU - Zincke, Horst

AU - Bostwick, David G.

PY - 1999/8/15

Y1 - 1999/8/15

N2 - BACKGROUND. Dedifferentiation is a distinctive feature of cancer progression. Detailed histologic analysis of primary prostate carcinoma and synchronous lymph node metastases may improve our understanding of the complex process of cancer progression and metastasis. METHODS. The authors studied 242 regional lymph node positive prostate carcinoma patients who underwent radical prostatectomy and bilateral lymphadenectomy between 1987 and 1992 at the Mayo Clinic. Patients ranged in age from 47-79 years (median, 66 years). The median follow-up was 6.1 years. Gleason scores of lymph node metastases and primary tumors were compared and correlated with systemic disease progression. Histologic dedifferentiation was defined as a higher Gleason grade in the lymph node metastases than in the primary tumor. Systemic disease progression was defined as the presence of distant metastases documented by biopsies, abdominal computed tomography, plain radiograph, or bone scan. RESULTS. The 5-year systemic progression free survival (PFS) rate was 90%. The Gleason score in the lymph node metastases was higher than in the primary tumor in 45% of patients, lower in 12% of patients, and matched exactly in 43% of patients. The 5-year PFS was significantly different between patients with histologic dedifferentiation (88% ± 3) and those without dedifferentiation (94% ± 2) (P = 0.04). Adjusting for the Gleason grade of the primary tumor and total lymph node tumor volume, the relative risk for disease progression associated with dedifferentiation was 1.8 (95% confidence interval, 0.7-4.7; P = 0.25). CONCLUSIONS. The findings of the current study demonstrate the morphologic heterogeneity of metastases from prostate carcinoma. There is a trend toward histologic dedifferentiation when prostate carcinoma metastasizes to regional lymph nodes. This dedifferentiation, although univariately significant, was not associated with disease progression when adjusted for lymph node tumor volume.

AB - BACKGROUND. Dedifferentiation is a distinctive feature of cancer progression. Detailed histologic analysis of primary prostate carcinoma and synchronous lymph node metastases may improve our understanding of the complex process of cancer progression and metastasis. METHODS. The authors studied 242 regional lymph node positive prostate carcinoma patients who underwent radical prostatectomy and bilateral lymphadenectomy between 1987 and 1992 at the Mayo Clinic. Patients ranged in age from 47-79 years (median, 66 years). The median follow-up was 6.1 years. Gleason scores of lymph node metastases and primary tumors were compared and correlated with systemic disease progression. Histologic dedifferentiation was defined as a higher Gleason grade in the lymph node metastases than in the primary tumor. Systemic disease progression was defined as the presence of distant metastases documented by biopsies, abdominal computed tomography, plain radiograph, or bone scan. RESULTS. The 5-year systemic progression free survival (PFS) rate was 90%. The Gleason score in the lymph node metastases was higher than in the primary tumor in 45% of patients, lower in 12% of patients, and matched exactly in 43% of patients. The 5-year PFS was significantly different between patients with histologic dedifferentiation (88% ± 3) and those without dedifferentiation (94% ± 2) (P = 0.04). Adjusting for the Gleason grade of the primary tumor and total lymph node tumor volume, the relative risk for disease progression associated with dedifferentiation was 1.8 (95% confidence interval, 0.7-4.7; P = 0.25). CONCLUSIONS. The findings of the current study demonstrate the morphologic heterogeneity of metastases from prostate carcinoma. There is a trend toward histologic dedifferentiation when prostate carcinoma metastasizes to regional lymph nodes. This dedifferentiation, although univariately significant, was not associated with disease progression when adjusted for lymph node tumor volume.

KW - Dedifferentiation

KW - Metastasis

KW - Progression

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=0033566783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033566783&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990815)86:4<657::AID-CNCR15>3.0.CO;2-9

DO - 10.1002/(SICI)1097-0142(19990815)86:4<657::AID-CNCR15>3.0.CO;2-9

M3 - Article

C2 - 10440694

AN - SCOPUS:0033566783

VL - 86

SP - 657

EP - 663

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -